NASDAQ:ZGNX - Zogenix Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$44.70 -2.85 (-5.99 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$44.70
Today's Range$44.00 - $47.80
52-Week Range$10.05 - $48.75
Volume1.03 million shs
Average Volume526,591 shs
Market Capitalization$1.67 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.76
Zogenix logoZogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.

Receive ZGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for ZGNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ZGNX
CUSIP98978L10
Phone510-550-8300

Debt

Debt-to-Equity RatioN/A
Current Ratio12.19
Quick Ratio12.19

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.82 million
Price / Sales160.32
Cash FlowN/A
Price / CashN/A
Book Value$8.80 per share
Price / Book5.08

Profitability

EPS (Most Recent Fiscal Year)($4.02)
Net Income$-126,810,000.00
Net MarginsN/A
Return on Equity-66.94%
Return on Assets-40.43%

Miscellaneous

Employees68
Outstanding Shares35,220,000

The Truth About Cryptocurrencies

Zogenix (NASDAQ:ZGNX) Frequently Asked Questions

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) announced its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.87) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.74) by $0.13. During the same quarter in the prior year, the company earned ($0.86) earnings per share. View Zogenix's Earnings History.

What price target have analysts set for ZGNX?

5 brokerages have issued 12 month price objectives for Zogenix's stock. Their predictions range from $51.00 to $56.00. On average, they anticipate Zogenix's stock price to reach $54.00 in the next year. View Analyst Ratings for Zogenix.

What are Wall Street analysts saying about Zogenix stock?

Here are some recent quotes from research analysts about Zogenix stock:
  • 1. According to Zacks Investment Research, "Zogenix, Inc. is a pharmaceutical company engaged in the development and commercialization of treatment products for central nervous system disorders and pain. Its first commercial product, Sumavel™ DosePro™ is a needle-free Delivery System used in the treatment of acute migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, ZX002, is a novel, oral and single-entity controlled-release formulation of hydrocodone used for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix, Inc. is headquartered in San Diego, CA. " (6/21/2018)
  • 2. Mizuho analysts commented, "We are confident ahead of this data and we expect the readout to be an important share moving event and the last major hurdle prior to submission of the NDA." (5/10/2018)

Who are some of Zogenix's key competitors?

Who are Zogenix's key executives?

Zogenix's management team includes the folowing people:
  • Dr. Stephen J. Farr, Co-Founder, CEO, Pres & Director (Age 59)
  • Mr. Roger L. Hawley B.S., Co-Founder & Director (Age 65)
  • Mr. Michael P. Smith, Exec. VP, CFO, Treasurer & Sec. (Age 50)
  • Dr. Bradley S. Galer, Exec. VP & Chief Medical Officer (Age 56)
  • Dr. Gail M. Farfel, Exec. VP & Chief Devel. Officer (Age 54)

Has Zogenix been receiving favorable news coverage?

News headlines about ZGNX stock have trended somewhat positive on Saturday, Accern Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Zogenix earned a media sentiment score of 0.07 on Accern's scale. They also assigned headlines about the company an impact score of 46.57 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Zogenix's major shareholders?

Zogenix's stock is owned by many different of retail and institutional investors. Top institutional investors include Scopia Capital Management LP (9.86%), BlackRock Inc. (7.48%), Farallon Capital Management LLC (4.47%), venBio Select Advisor LLC (3.38%), Eagle Asset Management Inc. (2.84%) and Franklin Resources Inc. (2.50%). Company insiders that own Zogenix stock include Bradley S Galer, Cam L Garner, Gail M Farfel, Life Sciences Maste Perceptive, Renee P Tannenbaum and Roger Hawley. View Institutional Ownership Trends for Zogenix.

Which major investors are selling Zogenix stock?

ZGNX stock was sold by a variety of institutional investors in the last quarter, including VHCP Management II LLC, venBio Select Advisor LLC, BlackRock Inc., DAFNA Capital Management LLC, JPMorgan Chase & Co., Highland Capital Management LP, Eversept Partners LLC and Gagnon Securities LLC. Company insiders that have sold Zogenix company stock in the last year include Cam L Garner, Gail M Farfel and Roger Hawley. View Insider Buying and Selling for Zogenix.

Which major investors are buying Zogenix stock?

ZGNX stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Artal Group S.A., GW&K Investment Management LLC, Point72 Asset Management L.P., Eventide Asset Management LLC, Millennium Management LLC, Scopia Capital Management LP and Cheyne Capital Management UK LLP. Company insiders that have bought Zogenix stock in the last two years include Bradley S Galer, Life Sciences Maste Perceptive and Renee P Tannenbaum. View Insider Buying and Selling for Zogenix.

How do I buy shares of Zogenix?

Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zogenix's stock price today?

One share of ZGNX stock can currently be purchased for approximately $44.70.

How big of a company is Zogenix?

Zogenix has a market capitalization of $1.67 billion and generates $9.82 million in revenue each year. The company earns $-126,810,000.00 in net income (profit) each year or ($4.02) on an earnings per share basis. Zogenix employs 68 workers across the globe.

How can I contact Zogenix?

Zogenix's mailing address is 5858 Horton Street Suite 455, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected]


MarketBeat Community Rating for Zogenix (ZGNX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  278 (Vote Outperform)
Underperform Votes:  180 (Vote Underperform)
Total Votes:  458
MarketBeat's community ratings are surveys of what our community members think about Zogenix and other stocks. Vote "Outperform" if you believe ZGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.